ABSTRACT
Significant progress has been achieved in the treatment of breast cancer with therapeutics focused on DNA replication or cell division. Despite the armamentarium of cytotoxic agents, enthusiasm for these agents has been tempered by their lack of tumor cell selectivity, toxicity profile, and almost uniformly the emergence of resistance.
